Skip to main content

Advertisement

SpringerLink
Log in

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer

  • Research Commentary
  • Published:
Tumor Biology

Abstract

Protein phosphatase 2A (PP2A) is a well-known tumor suppressor frequently inhibited in human cancer. Alterations affecting PP2A subunits together with the deregulation of endogenous PP2A inhibitors such as CIP2A and SET have been described as contributing mechanisms to inactivate PP2A in prostate cancer. Moreover, recent findings highlight that functional inactivation of PP2A could represent a key event in the acquisition of castration-resistant phenotype and a novel molecular target with high impact at both clinical and therapeutic levels in prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huang J, Jia J, Tong Q, Liu J, Qiu J, Sun R, et al. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy. Tumour Biol. 2015;36:1589–94.

    Article  CAS  PubMed  Google Scholar 

  2. Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015; In press.

  3. Huang PH, Wang D, Chuang HC, Wei S, Kulp SK, Chen CS. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis. 2009;30:1125–31.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bhardwaj A, Singh S, Srivastava SK, Honkanen RE, Reed E, Singh AP. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther. 2011;10:720–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21:795–807.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Khanna A, Rane JK, Kivinummi KK, Urbanucci A, Helenius MA, Tolonen TT, et al. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget. 2015; In press.

  7. Guo Z, Liu D, Su Z. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway. Tumour Biol. 2015;36:3583–9.

    Article  CAS  PubMed  Google Scholar 

  8. Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Pusey M, Nickels JT Jr, et al. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells. Tumour Biol 2015; In press.

  9. Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Nickels JT Jr, Rice LM. Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin. Tumour Biol 2015; In press.

  10. Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, et al. Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer. Mar Drugs. 2015;13:3276–86.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bhardwaj A, Singh S, Srivastava SK, Arora S, Hyde SJ, Andrews J, et al. Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br J Cancer. 2014;110:2000–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, et al. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res. 2013;11:568–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pandey P, Seshacharyulu P, Das S, Rachagani S, Ponnusamy MP, Yan Y, et al. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer. 2013;108:2590–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mukhopadhyay A, Tabanor K, Chaguturu R, Aldrich JV. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther. 2013;14:962–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Financial support

This study is supported by the Biobank of “Fundación Jiménez Díaz” (FJD Biobank) (RD12/0036/0021), and PI12/01552 and PI13/02609 grants from “Instituto de Salud Carlos III FEDER” and S2010/BMD2344. R. Manso and P. González-Alonso are supported by “Fundación Conchita Rábago de Jiménez Díaz”.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Pathology Department, IIS “Fundación Jiménez Diaz”, Avda. Reyes Católicos-2, 28040, Madrid, Spain

    Paula González-Alonso, Rebeca Manso, Juan Madoz-Gúrpide & Federico Rojo

  2. Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital “Fundacion Jimenez Diaz”, Avda. Reyes Católicos-2, 28040, Madrid, Spain

    Ion Cristóbal & Jesús García-Foncillas

Authors
  1. Paula González-Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ion Cristóbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebeca Manso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Madoz-Gúrpide
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jesús García-Foncillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Federico Rojo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federico Rojo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

González-Alonso, P., Cristóbal, I., Manso, R. et al. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer. Tumor Biol. 36, 5753–5755 (2015). https://doi.org/10.1007/s13277-015-3849-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3849-5

Keywords

Search

Navigation